Share

Market insight in association with

Watch Alibaba instead of Amazon in healthcare

In order to predict Amazon’s moves into healthcare, the market should look towards the Chinese online retail giant Alibaba, which already has a well-established healthcare offering, according to GlobalData Financial Services.

Amazon is regarded as an innovative company that has the potential to disrupt any industry it chooses to enter. Its threat derives from its large-scale distribution network and wide consumer reach. The healthcare industry has had a particularly watchful eye on Amazon since it announced a collaboration with Berkshire Hathaway and JP Morgan to create a healthcare company to serve its US employees in January 2018.

Amazon’s latest announcement in US healthcare is the purchase of the online PillPack. The start-up packages medication by dose and delivers it directly to patients in addition to vitamins, inhalers, and test supplies. The purchase of PillPack will allow Amazon to enter into retail pharmacy on a large scale, making use of its delivery network.

But this is not the first time an online retailer has entered the healthcare industry. While Amazon’s announcements are new to the European and US markets, Amazon’s business model could be said to be inspired by the Chinese online retail platform giant, Alibaba.

Alibaba’s proposition in health is older and more established than Amazon’s. Its subsidiary, Ali Health, provides a range of health services:

  • Medication delivery: Allows customers to purchase medication and health products online.
  • Doctor network: A network of doctors which customers can select based on their symptoms and communicate with online.
  • Health management: Apps and medical devices to help individuals manage their health. Advice and coaching can be customised to individuals’ needs, for instance regarding pregnancy or weight loss. Customers can purchase smart devices to monitor their blood pressure and glucose levels. They will also be recommended relevant health products to buy.
  • Health insurance: Online health insurance.
  • Product traceability: Provides a service to trace the origin of products including medication.
  • Artificial intelligence-assisted diagnosis tools

Alibaba’s model might be the type of offering Amazon seeks to emulate. If the European and US markets want to predict Amazon’s next move in healthcare, they may be best looking towards Asia.

For more insight and data, visit the GlobalData Report Store.

Share this article

Go to article: Home | Trust In Big PharmaGo to article: EditorialGo to article: NSFGo to article: ContentsGo to article: Daiichi JitsugyoGo to article: NewsGo to article: FreudenbergGo to article: The Pharma Industry BriefingGo to article: Fisher Clinical Services Company InsightGo to article: Fisher Clinical ServicesGo to article: The People vs Big Pharma: tackling the industry’s trust issuesGo to article: Scandinavian Health Ltd. Company InsightGo to article: Scandinavian Health Ltd.Go to article: Humira: the highs and lows of the world’s most successful drug Go to article: Wilhelm Haselmeier GmbH & Co KG Company InsightGo to article: Wilhelm Haselmeier GmbH & Co. KGGo to article: Gene therapy: talking smart solutions with Bluebird BioGo to article: Moehs Iberica Company InsightGo to article: Moehs Iberica SLGo to article: A research headache: improving the understanding of chronic migraine Go to article: SensitechGo to article: HOF Sonderanlagenbau Company InsightGo to article: HOF SonderanlagenbauGo to article: Philanthropy in pharma: a look inside the ISPE FoundationGo to article: DelSiTechGo to article: Novel Oral Therapies Are An Unmet Need For Ulcerative ColitisGo to article: PhoenixGo to article: FDA removes key barrier to US biosimilar developmentGo to article: Nipro PharmaPackagingGo to article: Pfizer price hikes: do rare cancer drugs warrant higher prices?Go to article: AlpexGo to article: Head-to-head: competing for the most effective psoriasis drugGo to article: Mecmesin Company InsightGo to article: MecmesinGo to article: Takeda to seek label expansion for Ninlaro in multiple myelomaGo to article: Capsugel Company InsightGo to article: Contract Pharmaceuticals Limited CanadaGo to article: Epilepsy: Zogenix’s ZX008 set for showdown with GW Pharma’s EpidiolexGo to article: EcocoolGo to article: Abiogen PharmaGo to article: Illegal online pharmacies: how endemic are they?Go to article: Global Freight Solutions LtdGo to article: The boom in medical cannabis research is set to continueGo to article: AtoZ-CRO GmbH Company InsightGo to article: AtoZ-CRO GmbHGo to article: Population boom will boost acute stroke market, particularly in ChinaGo to article: Pall BiotechGo to article: Cryo StoreGo to article: Watch Alibaba instead of Amazon in healthcareGo to article: WIKA - Disaster preventionGo to article: AstraZeneca’s Lynparza maintains lead in PARP inhibitor raceGo to article: G.F.Go to article: Erdmann Design SwitzerlandGo to article: CMV presents a serious concern in HIV+ personsGo to article: BEA TechnologiesGo to article: BaxterGo to article: bDMARD therapy: adherence in the first year is key to successGo to article: Pharma Support Services Ltd Company InsightGo to article: Pharma Support Services LtdGo to article: End the struggle: pathways to HEAL the opioid crisisGo to article: LaudaGo to article: AbbVie poised to overtake Gilead as hepatitis C leaderGo to article: ILC Dover IncGo to article: ViiV results show the importance of INIs to future HIV treatmentGo to article: PfanstiehlGo to article: Novartis acquires rights to atopic dermatitis candidate MOR106Go to article: Niconex Medical LtdGo to article: EventsGo to article: Next issue